CO2022007910A2 - Tratamientos contra el cáncer dirigidos a las células madre cancerosas - Google Patents
Tratamientos contra el cáncer dirigidos a las células madre cancerosasInfo
- Publication number
- CO2022007910A2 CO2022007910A2 CONC2022/0007910A CO2022007910A CO2022007910A2 CO 2022007910 A2 CO2022007910 A2 CO 2022007910A2 CO 2022007910 A CO2022007910 A CO 2022007910A CO 2022007910 A2 CO2022007910 A2 CO 2022007910A2
- Authority
- CO
- Colombia
- Prior art keywords
- cancer
- compounds
- stem cells
- kits
- compositions
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 210000000130 stem cell Anatomy 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000024313 Testicular Neoplasms Diseases 0.000 abstract 1
- 206010057644 Testis cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 201000003120 testicular cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962931531P | 2019-11-06 | 2019-11-06 | |
| PCT/US2020/059329 WO2021092322A1 (en) | 2019-11-06 | 2020-11-06 | Cancer treatments targeting cancer stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022007910A2 true CO2022007910A2 (es) | 2022-08-19 |
Family
ID=73643356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0007910A CO2022007910A2 (es) | 2019-11-06 | 2022-06-03 | Tratamientos contra el cáncer dirigidos a las células madre cancerosas |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4055008A1 (https=) |
| JP (2) | JP7690470B2 (https=) |
| KR (1) | KR20220110744A (https=) |
| CN (2) | CN119930509A (https=) |
| AU (1) | AU2020378067A1 (https=) |
| BR (1) | BR112022008753A2 (https=) |
| CA (1) | CA3157315A1 (https=) |
| CO (1) | CO2022007910A2 (https=) |
| IL (1) | IL292718A (https=) |
| MX (1) | MX2022005445A (https=) |
| PH (1) | PH12022551081A1 (https=) |
| WO (1) | WO2021092322A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102831570B1 (ko) | 2018-05-04 | 2025-07-10 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
| JP2024518089A (ja) * | 2021-05-13 | 2024-04-24 | リメディー プラン，インコーポレーテッド | Ｎａｍｐｔ阻害剤とその使用 |
| WO2024049225A1 (ko) | 2022-09-01 | 2024-03-07 | 주식회사 엘지에너지솔루션 | 이차 전지 및 이를 포함하는 디바이스 |
| CN116139141A (zh) * | 2022-12-14 | 2023-05-23 | 复旦大学 | Agk2促进肝癌的免疫治疗的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| WO2008016643A2 (en) * | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| FR2921657A1 (fr) * | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| CA2877474A1 (en) * | 2011-06-20 | 2012-12-27 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| HK1211832A1 (zh) | 2012-05-07 | 2016-10-14 | The General Hospital Corporation | 用於癌症療法的抗高血壓藥物的新穎配方及用法 |
| ES2774330T3 (es) | 2013-04-09 | 2020-07-20 | Massachusetts Inst Technology | Polímero de suministro de fármaco y usos del mismo |
| TW201625641A (zh) * | 2014-05-22 | 2016-07-16 | 健臻公司 | Ｎａｍｐｔ抑制劑及方法 |
| US11078195B2 (en) * | 2016-03-17 | 2021-08-03 | Checkmate Therapeutics Inc. | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same |
| KR102831570B1 (ko) * | 2018-05-04 | 2025-07-10 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
-
2020
- 2020-11-06 AU AU2020378067A patent/AU2020378067A1/en active Pending
- 2020-11-06 EP EP20816347.7A patent/EP4055008A1/en active Pending
- 2020-11-06 CA CA3157315A patent/CA3157315A1/en active Pending
- 2020-11-06 MX MX2022005445A patent/MX2022005445A/es unknown
- 2020-11-06 PH PH1/2022/551081A patent/PH12022551081A1/en unknown
- 2020-11-06 KR KR1020227018395A patent/KR20220110744A/ko active Pending
- 2020-11-06 JP JP2022526226A patent/JP7690470B2/ja active Active
- 2020-11-06 BR BR112022008753A patent/BR112022008753A2/pt unknown
- 2020-11-06 WO PCT/US2020/059329 patent/WO2021092322A1/en not_active Ceased
- 2020-11-06 CN CN202510009927.XA patent/CN119930509A/zh active Pending
- 2020-11-06 CN CN202080091217.1A patent/CN114929672B/zh active Active
-
2022
- 2022-05-03 IL IL292718A patent/IL292718A/en unknown
- 2022-06-03 CO CONC2022/0007910A patent/CO2022007910A2/es unknown
-
2025
- 2025-05-29 JP JP2025089886A patent/JP2025143254A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025143254A (ja) | 2025-10-01 |
| JP7690470B2 (ja) | 2025-06-10 |
| PH12022551081A1 (en) | 2024-06-19 |
| MX2022005445A (es) | 2022-08-10 |
| EP4055008A1 (en) | 2022-09-14 |
| CN114929672B (zh) | 2025-01-21 |
| IL292718A (en) | 2022-07-01 |
| AU2020378067A1 (en) | 2022-05-26 |
| CN119930509A (zh) | 2025-05-06 |
| JP2022553865A (ja) | 2022-12-26 |
| WO2021092322A1 (en) | 2021-05-14 |
| CN114929672A (zh) | 2022-08-19 |
| BR112022008753A2 (pt) | 2022-07-19 |
| CA3157315A1 (en) | 2021-05-14 |
| US20230023124A1 (en) | 2023-01-26 |
| KR20220110744A (ko) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022007910A2 (es) | Tratamientos contra el cáncer dirigidos a las células madre cancerosas | |
| JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| NZ784224A (en) | Parp1 inhibitors | |
| MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
| CO2020003478A2 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| CL2019001709A1 (es) | Derivados pirazol como inhibidores de malt1. | |
| JOP20190254A1 (ar) | مركبات مضادة للأورام | |
| CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
| MX384948B (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos. | |
| MX382562B (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub). | |
| MX392026B (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| MX2020005640A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. | |
| MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| NZ726365A (en) | Combinations for treating cancers | |
| PH12020551543A1 (en) | Therapeutic modulators of the reverse mode of atp synthase | |
| EA201400595A1 (ru) | Морфолинилбензотриазины для применения в лечении рака | |
| MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
| MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
| SA522432999B1 (ar) | C-17 مركبات تراي تريبينويد تخليقية ذات مجموعات استبدال اساسها نيتروجين عند وطرق استخدامها | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| MX2021009426A (es) | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. | |
| CO2022016819A2 (es) | Compuestos novedosos útiles como inhibidores de poli(adp-ribosa) polimerasa (parp) | |
| MX2024012392A (es) | Terapia combinada para el tratamiento del cancer |